Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EPS (Weighted Average and Diluted) (2022 - 2025)

TriSalus Life Sciences' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.12 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 70.0% year-over-year to -$0.12; the TTM value through Dec 2025 reached -$1.74, down 30.83%, while the annual FY2025 figure was -$1.84, 40.46% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q4 2025 per TLSIW's latest filing, up from -$0.96 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q1 2022 to a low of -$79.38 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$9.11, with a median of -$0.4 recorded in 2024.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 99.46% in 2023 against a maximum downside of 44900.0% in 2023.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$79.38 in 2022, then surged by 98.68% to -$1.05 in 2023, then skyrocketed by 61.9% to -$0.4 in 2024, then surged by 70.0% to -$0.12 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's EPS (Weighted Average and Diluted) are -$0.12 (Q4 2025), -$0.96 (Q3 2025), and -$0.27 (Q2 2025).